Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors : Consensus Round Table, Scottsdale (Arizona), March 22, 1987

The secretion of bioactive products by tumors of the gastroenteropancreatic system results in the development of watery diarrhea that can lead to death in a very short period if not brought under control. Even if the consequences are less dramatic, the patients' ability to lead a normal daily life is seriously impaired, and they may become severely depressed. SandostatinR alleviates the condition by inhibiting peptide release, and its long duration of action makes it an effective and rational adjunct to therapy at all stages. Last year a consensus Round Table Meeting was held in Scottsdale, Arizona, to discuss the optimal use of SandostatinR in this indication. These guidelines offer the results of clinical research and the dosage recommendations arising from them, together with a critical summary of the points of view presented. Front Matter....Pages I-VIII Prologue....Pages 1-2 Chemical Structure — Pharmacological Profile of Sandostatin®....Pages 3-13 Carcinoid Tumours and the Carcinoid Syndrome....Pages 15-22 Tumors of the Gastroenteropancreatic Axis....Pages 23-38 The Use of Sandostatin® in Insulinomas. The Relation Between In Vivo Responses, the Presence of Somatostatin Receptors and the Development of Tachyphylaxis....Pages 39-42 Sandostatin®: Assay and Efficacy in VIPoma and Insulinoma....Pages 43-48 Sandostatin® in Digestive Endocrine Tumors....Pages 49-52 VIPoma, Gastrinoma and Glucagonoma....Pages 53-57 Rebound Effect and Escape of Diarrhea Inhibition Using Sandostatin® in VIPoma Patients....Pages 59-60 Long-Term Treatment of VIPoma and Glucagonoma with Sandostatin®....Pages 61-64 Therapy of the Malignant Carcinoid Syndrome and Metastatic Islet Cell Carcinoma....Pages 65-82 Sandostatin® in the Treatment of Advanced Malignancies....Pages 83-87 Treatment of Malignant Neuroendocrine Gut and Pancreatic Tumors with Sandostatin®....Pages 89-92 Sandostatin® and Gastroenteropancreatic Endocrine Tumors — Therapeutic Characteristics....Pages 93-113 Consensus....Pages 115-117 Future Directions....Pages 119-120 Back Matter....Pages 121-146